IL-2 in Refractory Autoimmune Encephalitis
NCT02714959 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2021-09-29
Summary
The purpose of this study is to determine whether low-dose IL-2 is effective in refractory autoimmune encephalitis.
Conditions
Interventions
- DRUG
-
Proleukin
Sponsors & Collaborators
-
Seoul National University Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 19 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-03-31
- Primary Completion
- 2019-06-12
- Completion
- 2019-06-12
More Related Trials
-
IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis
NCT04697407 ·Status: COMPLETED ·Phase: NA
-
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
NCT01412333 ·Status: COMPLETED ·Phase: PHASE3
-
REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients
NCT01171209 ·Status: COMPLETED ·Phase: PHASE2
-
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
NCT04781309 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic
NCT05056740 ·Status: RECRUITING
-
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
NCT00207727 ·Status: COMPLETED ·Phase: PHASE2
-
Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients
NCT00928967 ·Status: COMPLETED
-
Natalizumab Subcutaneous Immunogenicity and Safety Study
NCT02142192 ·Status: TERMINATED ·Phase: PHASE2
-
Intrathecal Rituximab in Progressive Multiple Sclerosis
NCT02545959 ·Status: COMPLETED ·Phase: PHASE2
-
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
NCT05072691 ·Status: RECRUITING
-
Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis
NCT05078177 ·Status: UNKNOWN ·Phase: PHASE1
-
EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis
NCT00146068 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
NCT01247324 ·Status: COMPLETED ·Phase: PHASE3
-
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
NCT03344094 ·Status: COMPLETED
-
Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab
NCT01250678 ·Status: UNKNOWN
-
Zenapax to Treat Multiple Sclerosis
NCT00001934 ·Status: COMPLETED ·Phase: PHASE2
-
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00917839 ·Status: UNKNOWN ·Phase: PHASE2
-
Differential Immune Effects of Natalizumab
NCT00859482 ·Status: COMPLETED
-
IL-11 in the Development of Multiple Sclerosis
NCT03735823 ·Status: UNKNOWN
-
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT00882999 ·Status: COMPLETED ·Phase: PHASE2
-
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
NCT05849467 ·Status: RECRUITING ·Phase: PHASE1
-
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
NCT06677710 ·Status: SUSPENDED ·Phase: PHASE1
-
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
NCT01201343 ·Status: COMPLETED ·Phase: PHASE4
-
Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab
NCT02856451 ·Status: COMPLETED
-
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
NCT00382629 ·Status: COMPLETED ·Phase: PHASE2